Please type a plus sign (+) inside this box	\rightarrow	\Box
Under the Paperwork Reduction Act of 1995,	no persons	are r

PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION **TRANSMITTAL**

A068 US Attorney Docket No. Rennert First Inventor Antagonists of Tweak and of Tweak Receptor...

		1100
(Only for new nonprovision	onal applications under 37 CFR 1.53(b))	Express Mail Label No. EL475127482US
	ATION ELEMENTS seeming utility patent application contents.	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application
	Form (e.g., PTO/SB/17)	Washington, DC 20231
(Submit an original and a	a duplicate for fee processing)	CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
2. Applicant claims : See 37 CFR 1.27	small entity status.	Nucleotide and/or Amino Acid Sequence Submission
Specification	[Total Pages 26]	(if applicable, all necessary)
(preierred arrangemen	e of the invention	a. Computer Readable Form (CRF)
 Cross Reference 	ce to Related Applications	b. Specification Sequence Listing on:
- Statement Reg	parding Fed sponsored R & D equence listing, a table,	i. 🗶 CD-ROM or CD-R (2 copies); or
or a computer _l	program listing appendix	ii. 🗶 paper
- Background of	the Invention of the Invention	c X Statements verifying identity of above copies
- Brief Description	on of the Drawings (if filed)	ACCOMPANYING APPLICATION PARTS
 Detailed Descr 	iption	Assignment Papers (cover sheet & document(s))
- Claim(s) - Abstract of the	Disclosure	10. 37 CFR 3.73(b) Statement Power of Attorney
4. X Drawing(s) (35 U	J.S.C. 113) [Total Sheets 5]	11. English Translation Document (if applicable)
5. Oath or Declaration	[Total Pages 2]	12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations
a. Newly exec	uted (original or copy)	13. Preliminary Amendment
b. Copy from a	a prior application (37 CFR 1.63 (d)) attion/divisional with Box 18 completed)	14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
i. DELET	ION OF INVENTOR(S) atement attached deleting inventor(s)	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)
named in	the prior application, see 37 CFR	Request and Certification under 35 U.S.C. 122
1.63(d)(2)	and 1.33(b)	(b)(2)(B)(i). Applicant must attach form PTO/SB/35
6. Application Data	Sheet. See 37 CFR 1.76	or its equivalent.
		17. Other:
or in an Application Data She	CATION, check appropriate box, and sup	oly the requisite information below and in a preliminary amendment,
Continuation	Divisional Continuation-in-part (CIP)	
Prior application information:	Examiner Continuation File Part (CIF)	of prior application No.
For CONTINUATION OR DIVISI	ONAL APPS only: The entire disclosure of the	Group Art Unit:
		re prior application, from which an oath of declaration is supplied under action or divisional application and is hereby incorporated by reference. tently omitted from the submitted application parts.
	19. CORRESPOND	ENCE ADDRESS
Customer Number or Bar Co	ode Label firiseit Customer No. or Attach be	or X Correspondence address below
Name	Timothy P. Linkkila	
	BIOGEN, INC.	
Address	14 Cambridge Center	
City	Cambridge	State MA Zip Code 02142
Country	USA Tel	ephone (617) 679-3795 Fax (617) 679-2838
Name (Print/Type)	Timothy P. Linkkila	Registration No. (Attorney/Agent) 40,702
Signature	Timothy P. Ji	Akile Date 7/13/01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO. Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/17 (09-00)
Approved for use through 10/31/2002, OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

6

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT	(\$)	74

Complete if Known			
Application Number			
Filing Date	July 13, 2001		
First Named Inventor	Rennert, Paul		
Examiner Name			
Group Art Unit			
Attorney Docket No.	A068 US		

METHOD OF PATMENT	FEE CALCULATION (continued)			
1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to: 3. ADDITIONAL FEES				
Deposit Account 02 2227	Large Entity Small Entity Fee Fee Fee Fee Code (\$) Code (\$) Fee Description	Fee Paid		
Number 02-2327	Code (\$) Code (\$) 105 130 205 65 Surcharge - late filing fee or oath	T CC T ald		
Deposit Account Name BIOGEN, INC.	127 50 227 25 Surcharge - late provisional filing fee or			
Charge Any Additional Fee Required	cover sheet			
Under 37 CFR 1.16 and 1.17	139 130 139 130 Non-English specification			
Applicant claims small entity status See 37 CFR 1.27	147 2,520 147 2,520 For filing a request for ex parte reexamination			
2. Payment Enclosed:	112 920* 112 920* Requesting publication of SIR prior to Examiner action			
Check Credit card Money Order Other	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action			
FEE CALCULATION	115 110 215 55 Extension for reply within first month			
1. BASIC FILING FEE	116 390 216 195 Extension for reply within second month			
Large Entity Small Entity	117 890 217 445 Extension for reply within third month			
Fee Fee Fee Fee Description	118 1,390 218 695 Extension for reply within fourth month			
101 710 201 255 Uklibu films for	128 1,890 228 945 Extension for reply within fifth month			
106 320 206 160 Design filling fee 710	119 310 219 155 Notice of Appeal			
107 490 207 245 Plant filing fee	120 310 220 155 Filing a brief in support of an appeal			
108 710 208 355 Reissue filing fee	121 270 221 135 Request for oral hearing			
114 150 214 75 Provisional filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding			
	140 110 240 55 Petition to revive - unavoidable			
SUBTOTAL (1) (\$) 710	141 1,240 241 620 Petition to revive - unintentional			
2. EXTRA CLAIM FEES	142 1,240 242 620 Utility issue fee (or reissue)			
Fee from Ext <u>ra Clai</u> ms <u>below</u> Fee Paid	143 440 243 220 Design issue fee			
Total Claims	144 600 244 300 Plant issue fee			
Claims	122 130 122 130 Petitions to the Commissioner			
Multiple Dependent = 0	123 50 123 50 Petitions related to provisional applications			
Lorgo Entity Co., II E. C.	126 240 126 240 Submission of Information Disclosure Stmt			
Large Entity Small Entity Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)			
103 18 203 9 Claims in excess of 20	146 710 246 355 Filing a submission after final rejection			
102 80 202 40 Independent claims in excess of 3	(37 ČFR § 1 129(a)) 149 710 249 355 For each additional invention to be			
104 270 204 135 Multiple dependent claim, if not paid	149 710 249 355 For each additional invention to be examined (37 CFR § 1 129(b))			
109 80 209 40 ** Reissue independent claims over original patent	179 710 279 355 Request for Continued Examination (RCE)			
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	169 900 169 900 Request for expedited examination of a design application			
SUBTOTAL (2) (\$) 36	Other fee (specify)			
**or number previously paid, if greater; For Reissues, see above Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0				
SUBMITTED BY Complete (if applicable)				

Name (Print/Type) Registration No. Timothy P. Linkkila 40,702 Telephone (617) 679-3795 (Attorney/Agent) Signature

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

By the first street rather the first than the street street street street the street s

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

BIOGEN, INC.

Serial No.:

Not assigned yet

Filing Date:

Herewith

For:

Antagonists of Tweak and of Tweak Receptor and Their Use to

Treat Immunological Disorders

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office via Express Mail Label EL475127482US addressed to BOX PATENT APPLICATION, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date:

13 Auly 2007

Signature:

Patricia Hofstetter

STATEMENT REGARDING SEQUENCE LISTING

Applicant hereby submits a diskette containing a machine-readable copy of the Sequence Listing done in FastSEQ 4.0.

The contents of the paper and computer readable copies are the same and, include no new matter, as required by 37 C.F.R. 1.821 (e). The sequences on the diskette and on the paper listing are identical to the sequences submitted in the application as filed.

Please charge our deposit account 02-2327 for any deficiencies.

Respectfully submitted,

Date: 7/13/01

Timothy P. Linkkifa
Reg. No. 40,702

Reg. No. 40,702 BIOGEN, INC.

14 Cambridge Center Cambridge, MA 02142

(617) 679-3795

#7556